Patents by Inventor Steven B. Landau
Steven B. Landau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7125848Abstract: A method is provided for using Cav2.2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.Type: GrantFiled: June 10, 2004Date of Patent: October 24, 2006Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Matthew Oliver Fraser, Steven B. Landau, Edward C. Burgard
-
Patent number: 7115606Abstract: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity.Type: GrantFiled: June 7, 2004Date of Patent: October 3, 2006Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Steven B. Landau, Cheryl L. Miller, Matthew O. Fraser
-
Patent number: 7094786Abstract: Methods are disclosed for the treatment of nausea and vomiting in a patient suffering therefrom comprising administering 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine.Type: GrantFiled: May 14, 2004Date of Patent: August 22, 2006Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Steven B. Landau, Cheryl L. Miller, Karl B. Thor
-
Patent number: 7041704Abstract: The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat a gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.Type: GrantFiled: February 11, 2005Date of Patent: May 9, 2006Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Edward C. Burgard, Steven B. Landau, Matthew Oliver Fraser
-
Patent number: 6846823Abstract: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity.Type: GrantFiled: April 2, 2004Date of Patent: January 25, 2005Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Steven B. Landau, Cheryl L. Miller, Matthew O. Fraser
-
Publication number: 20040259862Abstract: The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.Type: ApplicationFiled: May 7, 2004Publication date: December 23, 2004Applicant: Dynogen, Inc.Inventor: Steven B. Landau
-
Publication number: 20040254171Abstract: The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.Type: ApplicationFiled: May 14, 2004Publication date: December 16, 2004Applicant: Dynogen, Inc.Inventors: Steven B. Landau, Cheryl L. Miller, Karl B. Thor
-
Publication number: 20040254169Abstract: The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.Type: ApplicationFiled: May 7, 2004Publication date: December 16, 2004Applicant: Dynogen, Inc.Inventor: Steven B. Landau
-
Publication number: 20040254172Abstract: The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.Type: ApplicationFiled: May 14, 2004Publication date: December 16, 2004Applicant: Dynogen, Inc.Inventors: Steven B. Landau, Cheryl L. Miller, Karl B. Thor
-
Publication number: 20040254168Abstract: The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.Type: ApplicationFiled: May 3, 2004Publication date: December 16, 2004Applicant: Dynogen, Inc.Inventor: Steven B. Landau
-
Publication number: 20040254170Abstract: The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.Type: ApplicationFiled: May 7, 2004Publication date: December 16, 2004Applicant: Dynogen, Inc.Inventor: Steven B. Landau
-
Publication number: 20040248979Abstract: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis comprising coadministering to said subject a first amount of an &agr;2&dgr; subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative, wherein the first and second amounts together comprise a therapeutically effective amount.Type: ApplicationFiled: June 3, 2004Publication date: December 9, 2004Applicant: DYNOGEN PHARMACEUTICALS, INC.Inventors: Lee R. Brettman, Steven B. Landau, Matthew O. Fraser
-
Publication number: 20040213842Abstract: The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.Type: ApplicationFiled: January 30, 2004Publication date: October 28, 2004Applicant: Dynogen Pharmaceuticals, Inc.Inventors: Edward C. Burgard, Steven B. Landau, Matthew Oliver Fraser
-
Publication number: 20040209869Abstract: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity.Type: ApplicationFiled: April 2, 2004Publication date: October 21, 2004Applicant: Dynogen Pharmaceuticals, Inc.Inventors: Steven B. Landau, Cheryl L. Miller, Mathew O. Fraser
-
Publication number: 20040198822Abstract: A method is provided for using &agr;2&dgr; subunit calcium channel modulators or other compounds that interact with the &agr;2&dgr; calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, &agr;2&dgr; subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, &bgr;3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.Type: ApplicationFiled: March 22, 2004Publication date: October 7, 2004Applicant: Dynogen Pharmacueticals, Inc.Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard, Lee R. Brettman, Steven B. Landau, Daniel J. Ricca
-
Publication number: 20040147510Abstract: The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.Type: ApplicationFiled: January 13, 2004Publication date: July 29, 2004Applicant: Dynogen Pharmaceuticals, Inc.Inventors: Steven B. Landau, Cheryl L. Miller, Karl B. Thor
-
Publication number: 20040147509Abstract: The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.Type: ApplicationFiled: January 13, 2004Publication date: July 29, 2004Applicant: Dynogen Pharmaceuticals, Inc.Inventor: Steven B. Landau